Authors

Suresh S. Ramalingam, MD, Emory University School of Medicine

Latest:

Exploring the Latest in EGFR-Mutant Lung Cancer With Drs Ramalingam and Raez

Luis E. Raez, MD, and Suresh S. Ramalingam, MD, FACP, FASCO, sit down with Chandler Park, MD, FACP, and Eric K. Singhi, MD, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.

Suresh S. Ramalingam, MD, FASCO, Winship Cancer Institute of Emory University

Latest:

Rapid Readouts: Three-Year Update From CheckMate 227, Part 1

Suresh S. Ramalingam, MD, Winship Cancer Institute

Latest:

Updates in Immunotherapy for Advanced Thoracic Malignancies

Suresh S. Ramalingam, MD, Winship Cancer InstitutePanelists: Benjamin P. Levy, MD, Sibley Memorial Hospital

Suresh Senan, MD, VU University Medical Center

Suresh Senan, MRCP, FRCR, PhD, VU University Medical Center

Suriya Jeyapalan, MD, MPH, Tufts Medical Center

Susan A. McCloskey, MD

Latest:

Dr. McCloskey on Postoperative Radiation in Patients With Breast Cancer

Susan A. McCloskey, MD, MSHS, assistant professor of radiation oncology, University of California Los Angeles (UCLA) Medical Center, Jonsson Comprehensive Cancer Center, discusses the evolution of postoperative radiation in patients with breast cancer.

Susan C. Modesitt, MD, FACS, FACOG

Latest:

Dr Modesitt on Shared Decision-Making When Choosing PARP Inhibitors in Ovarian Cancer

Susan C. Modesitt, MD, FACOG, FACS, discusses the role of PARP inhibitors in the treatment of patients with ovarian cancer.

Susan C. Pannullo, MD, Weill Cornell Brain

Susan Domchek, MD

Latest:

Dr Domchek on the Importance of Germline Testing in Breast Cancer Care

Susan Domchek, MD, FASCO, discusses the importance of germline testing in breast cancer care.

Susan E. Prockop, MD

Latest:

Dr. Prockop Discusses Tabelecleucel in Post-Transplant EBV+ Lymphomas

Susan E. Prockop, MD, pediatric oncologist, Memorial Sloan Kettering Cancer Center, discusses tabelecleucel in patients with Epstein-Barr virus (EBV)-associated post-transplant lymphomas.

Susan F. Slovin, MD, PhD

Latest:

Dr. Slovin on Considerations for Treatment Selection in Nonmetastatic CRPC

Susan F. Slovin, MD, PhD, discusses considerations for treatment selection in nonmetastatic castration-resistant prostate cancer.

Susan F. Slovin, MD, PhD, Memorial Sloan Kettering Cancer Center

Susan Galbraith, MD, PhD

Latest:

Dr. Galbraith Discusses Phase I/II Results for AZD9291 in Advanced NSCLC

Susan Galbraith, MD, PhD, head, Oncology Innovative Medicine, AstraZeneca, discusses updated data from the ongoing phase I/II AURA study looking at AZD9291 for NSCLC.

Susan Halabi, PhD

Latest:

Overall Survival Analysis Between African-American and Caucasian Men with mCRPC

Susan Halabi, PhD, professor of biostatistics and bioinformatics, School of Medicine, Duke Cancer Institute, discusses an analysis of overall survival (OS) between African-American and Caucasian men with metastatic castration-resistant prostate cancer.

Susan J. Hoover, MD, FACS

Latest:

Novel Radiotherapy Techniques Expand Options for Breast Cancer Patients

Those of us who have treated patients with breast cancer for any extended period of time can likely share anecdotes about watching the treatment of this disease evolve to levels many of us could only have imagined when we began practicing.

Susan Lutgendorf, PhD

Latest:

Susan Lutgendorf on Impact of Minimal Support on Patients With Ovarian Cancer

Susan Lutgendorf, PhD, professor and Starch Faculty Fellow, Psychological and Brain Sciences, College of Liberal Arts and Sciences, University of Iowa, discusses the impact of lack of support on patients with ovarian cancer. Lutgendorf spoke on this during an interview at the SITC 31st Annual Meeting and Associated Programs.

Susan M. O'Brien

Latest:

Dr. O'Brien Discusses Combination Venetoclax in CLL

Susan M. O’Brien, MD, hematologist/oncologist at University of California, Irvine Health, discusses combination venetoclax (Venclexta) in the treatment of patients with chronic lymphocytic leukemia.